Page last updated: 2024-12-05

lysergic acid diethylamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5761
CHEMBL ID263881
CHEBI ID6605
SCHEMBL ID113755
MeSH IDM0012833

Synonyms (173)

Synonym
gtpl17
(8beta)-n,n-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide
lisergido [inn-spanish]
dea no. 7315
diethylamid kyseliny lysergove [czech]
ergoline-8-carboxamide, 9,10-didehydro-n,n-diethyl-6-methyl-, (8beta)-
lysergic acid diethylamide tartrate
einecs 200-033-2
lysergidum [inn-latin]
lsd-25
ergoline-8beta-carboxamide, 9,10-didehydro-n,n-diethyl-6-methyl-
brn 0094179
lysergide [inn:ban:dcf]
9,10-didehydro-n,n-diethyl-6-methyl-ergoline-8-beta-carboxamide
lisergide [dcit]
ergoline-8-beta-carboxamide, 9,10-didehydro-n,n-diethyl-6-methyl-
wedding bells
PDSP2_001415
PDSP1_001540
PDSP2_001524
PDSP1_001431
cherry top
lsd 25
sunshine
d-lsd
lysergaure diethylamid
owsley
flats
mean green
blue cheer
blue acid
trippers
9,10-didehydro-n,n-diethyl-6-methylergoline-8b-carboxamide
hawk
lysergsaeurediaethylamid
chocolate chips
lysergsauerediaethylamid
mellow yellow
purple haze
orange sunshine
microdots
instant zen
yellows
blotter acid
purple microdot
haze
california sunshine
d-lysergic acid diethylamide
lysergic acid diethylamide-25
lysergamid
window pane
lsd (alkaloid)
clearlight
hsdb 3920
wedding bells acid
lids
orange wedges
cupcakes
big f
lysergamide, n,n-diethyl-
wedges
contact lens
chief
brown dots
delysid
the hawk
fifty
barrels
white light
ergoline-8b-carboxamide, 9,10-didehydro-n,n-diethyl-6-methyl- (8ci)
bartman
strawberry fields
royal blue
lucy in the sky with diamonds
sugar lump
bart simpson
scapes
blue star
beast
spoonies
cubes
pearly gates
paper acid
heavenly blue
orange mushroom
domes
ubergluben
blue mist
(+)-lysergic acid diethylamide
gelatin chips
greenies
lsd,(+)
lsd,l-
chembl263881 ,
[3h]-lsd
(4r,7r)-n,n-diethyl-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide
bdbm21342
LSD ,
lysergide
C07542
lysergic acid diethylamide
50-37-3
n,n-diethyl-d-lysergamide
DB04829
n,n-diethyllysergamide
n,n-diethyl-(+)-lysergamide
NCGC00168265-01
(8r)-9,10-didehydro-n,n-diethyl-6-methylergoline-8-carboxamide
CHEBI:6605 ,
lysergsaeurediethylamid
bdbm50241702
[n-methyl-3h]lsd
dextrolysergic acid diethylamide
lysergic acid diethylamide tartrate ci
NCGC00168265-02
diethylamide, lysergic acid
acid diethylamide, lysergic
dtxsid1023231 ,
dtxcid003231
tox21_113508
cas-50-37-3
tox21_112872
niosh/ke4200000
ergoline-8-beta-carboxamide, 9,10-didehydro-n,n-diethyl-6-methyl-, (-)-
lysergic acid diethylamide, l-isomer
KE42000000
lysergidum
pearly gates [street name]
cubes [street name]
4-25-00-00939 (beilstein handbook reference)
royal blue [street name]
diethylamid kyseliny lysergove
acid [street name]
8na5swf92o ,
heavenly blue [street name]
wedding bells [street name]
lisergido
unii-8na5swf92o
lisergide
SCHEMBL113755
(8.beta.)-9,10-didehydro-n,n-diethyl-6-methylergoline-8-carboxamide
lysergide [who-dd]
9,10-didehydro-n,n-diethyl-6-methyl-ergoline-8b-carboxamide
lysergide [inn]
lysergide [mi]
(6ar,9r)-n,n-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
lysergide [hsdb]
ergoline-8-carboxamide, 9,10-didehydro-n,n-diethyl-6-methyl-, (5.beta., 8.beta.)-
(+)-lysergide (incb:green list)
ergoline-8-carboxamide, 9,10-didehydro-n,n-diethyl-6-methyl-, (8b)-
7ld ,
(8alpha)-n,n-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide
lsd (lysergic acid diethylamide;lysergide)
lsd (lysergic acid diethylamide) 0.025 mg/ml in acetonitrile
lsd (lysergic acid diethylamide) 1.0 mg/ml in acetonitrile
lysergide (lsd)
Q23118
(6ar,9r)-n,n-diethyl-7-methyl-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide
9,10-didehydro-n,n-diethyl-6-methylergoline-8beta-carboxamide
indolo(4,3-fg)quinoline, ergoline-8-carboxamide deriv.
pearly gates (street name)
lisergida
cubes (street name)
acid (street name)
royal blue (street name)
ergoline-8-carboxamide, 9,10-didehydro-n,n-diethyl-6-methyl-, (5beta, 8beta)-
wedding bells (street name)
(8beta)-9,10-didehydro-n,n-diethyl-6-methylergoline-8-carboxamide
lysergidum (latin)
heavenly blue (street name)
lsd (d-lysergic acid n,n-diethylamide), 0.1mg/ml in acetonitrile
lsd (d-lysergic acid n,n-diethylamide)
lsd (d-lysergic acid n,n-diethylamide), 1mg/ml in acetonitrile

Research Excerpts

Overview

Lysergic acid diethylamide (LSD) is a prototypical hallucinogen and its psychedelic actions are exerted through the 5-HT. While phencyclidine (PCP) has increased in popularity in recent years, especially among the adolescents.

ExcerptReferenceRelevance
"Lysergic acid diethylamide (LSD) is a prototypical hallucinogen and its psychedelic actions are exerted through the 5-HT"( LSD-stimulated behaviors in mice require β-arrestin 2 but not β-arrestin 1.
Chiu, YT; Means, CR; Nadkarni, V; Pogorelov, VM; Rodriguiz, RM; Roth, BL; Wetsel, WC, 2021
)
1.34
"Lysergic acid diethylamide (LSD) is a classic hallucinogen, widely abused for decades, while phencyclidine (PCP) has increased in popularity in recent years, especially among the adolescents. "( Cytotoxic, genotoxic, and oxidative stress-related effects of lysergic acid diethylamide (LSD) and phencyclidine (PCP) in the human neuroblastoma SH-SY5Y cell line.
Jurič, A; Karačonji, IB; Katalinić, M; Kozina, G; Lovaković, BT; Pizent, A; Rašić, D; Vrdoljak, AL; Zandona, A, 2021
)
2.3
"Lysergic acid diethylamide (LSD) is a serotonergic psychedelic compound receiving increasing interest due to putative anxiolytic and antidepressant properties. "( Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline.
Comai, S; De Gregorio, D; El Rahimy, Y; Enns, JP; Gobbi, G; Inserra, A; Lopez-Canul, M; Markopoulos, A; Pileggi, M, 2022
)
2.58
"Lysergic acid diethylamide (LSD) is an atypical psychedelic compound that exerts its effects through pleiotropic actions, mainly involving 1A/2A serotoninergic (5-HT) receptor subtypes. "( Spatial Correspondence of LSD-Induced Variations on Brain Functioning at Rest With Serotonin Receptor Expression.
Carhart-Harris, RL; Chiacchiaretta, P; Della Penna, S; Delli Pizzi, S; Ferretti, A; Nutt, DJ; Onofrj, M; Roseman, L; Sensi, SL; Sestieri, C; Timmermann, C, 2023
)
2.35
"Lysergic acid diethylamide (LSD) is a potent classic serotonergic psychedelic, which facilitates a variety of altered states of consciousness. "( Dose-response relationships of LSD-induced subjective experiences in humans.
Hirschfeld, T; Majić, T; Prugger, J; Schmidt, TT, 2023
)
2.35
"Lysergic acid diethylamide (LSD) is a prevalent psychoactive substance recognized for its hallucinogenic properties, often encountered in blotter papers for illicit consumption. "( Comprehensive detection of lysergic acid diethylamide (LSD) in forensic samples using carbon nanotube screen-printed electrodes.
Alves de Barros, W; Arantes, LC; de Deus Melo, T; de Fátima, Â; Macedo, AA; Magalhães de Almeida Melo, L; Pimentel, DM; Pio Dos Santos, WT; Rocha, CM, 2023
)
2.65
"Lysergic acid diethylamide (LSD) is a potent hallucinogenic substance that was extensively investigated by psychiatrists during the 1950s and 1960s. "( Acute effects of lysergic acid diethylamide (LSD) on resting brain function.
Borgwardt, S; Müller, F, 2019
)
2.3
"Lysergic acid diethylamide (LSD) is a classic psychedelic, 3,4-methylenedioxymethamphetamine (MDMA) is an empathogen, and D-amphetamine is a classic stimulant. "( Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.
Borgwardt, S; Duerig, R; Eckert, A; Holze, F; Ley, L; Liechti, ME; Müller, F; Varghese, N; Vizeli, P, 2020
)
2
"Lysergic acid diethylamide (LSD) is a highly potent psychedelic drug derived from ergot alkaloids. "( Self-inflicted neck wounds under influence of lysergic acid diethylamide: A case report and literature review.
Baert, A; Bouvet, R; Gicquel, T; Le Daré, B; Morel, I, 2020
)
2.26
"Lysergic acid diethylamide (LSD) is an ergot alkaloid derivative with psychedelic properties that has been implicated in the management of persistent pain. "( A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers.
Dolder, P; Feilding, A; Holze, F; Hutten, N; Kuypers, KP; Liechti, ME; Mason, NL; Ramaekers, JG; Theunissen, EL, 2021
)
2.42
"Lysergic acid diethylamide (LSD) is a hallucinogen, synthesized from ergot alkaloid, and controlled as a narcotic in Japan. "( [Identification of LSD Derivatives, 1cP-LSD, MIPLA and 1B-LSD in Illegal Products as Paper Sheet].
Hakamatsuka, T; Kawamura, M; Kikura-Hanajiri, R; Tanaka, R, 2020
)
2
"Lysergic acid diethylamide (LSD) is a potent psychedelic drug, which has seen a revival in clinical and pharmacological research within recent years. "( Increased sensitivity to strong perturbations in a whole-brain model of LSD.
Atasoy, S; Carhart-Harris, R; Deco, G; Jobst, BM; Kaelen, M; Kringelbach, ML; Ponce-Alvarez, A; Roseman, L; Sanjuán, A, 2021
)
2.06
"Lysergic acid diethylamide (LSD) is a potent, hallucinogenic substance that distorts the perception, state of consciousness and behaviour of the user. "( An apathetic child with hallucinations.
Berg, JA; Brodwall, K; Teigen, IA, 2021
)
2.06
"Lysergic acid diethylamide (LSD) is a potent psychoactive substance that has attracted great interest in clinical research. "( Separating the wheat from the chaff: Observations on the analysis of lysergamides LSD, MIPLA, and LAMPA.
Auwärter, V; Blanckaert, P; Brandt, SD; Chapman, SJ; Dowling, G; Grill, M; Kavanagh, PV; Schwelm, HM; Stratford, A; Westphal, F, 2022
)
2.16
"Lysergic acid diethylamide (LSD) is a classic psychedelic substance that is used recreationally and investigated in psychiatric research. "( Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis.
Dolder, PC; Holze, F; Liechti, ME; Schmid, Y; Straumann, I; Vizeli, P, 2021
)
2.06
"Lysergic acid diethylamide (LSD) is a widely used recreational drug. "( Development and validation of an LC-MS/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial.
Dolder, PC; Liechti, ME; Rentsch, KM, 2018
)
2.16
"Lysergic acid diethylamide (LSD) is a powerful hallucinogen, active at very low dosages, with, as a direct consequence, potential difficulties to be detected and quantified in a clinical or forensic context, in body fluids and even more in hair. "( LSD Detection and Interpretation in Hair.
Allorge, D; Gaulier, JM; Richeval, C; Vanhoye, X, 2017
)
1.9
"Lysergic acid diethylamide (LSD) is a widely used recreational drug. "( Development and validation of a rapid turboflow LC-MS/MS method for the quantification of LSD and 2-oxo-3-hydroxy LSD in serum and urine samples of emergency toxicological cases.
Dolder, PC; Liechti, ME; Rentsch, KM, 2015
)
1.86
"Lysergic acid diethylamide (LSD) is a semisynthetic compound with strong psychoactive properties. "( A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects.
Liester, MB, 2014
)
2.22
"Lysergic acid diethylamide (LSD) is a potent serotonergic hallucinogen or psychedelic that modulates consciousness in a marked and novel way. "( The paradoxical psychological effects of lysergic acid diethylamide (LSD).
Bolstridge, M; Carhart-Harris, RL; Feilding, A; Kaelen, M; Nutt, DJ; Underwood, R; Williams, LT; Williams, TM, 2016
)
2.14
"Lysergic acid diethylamide (LSD) is a serotonin 5-hydroxytryptamine-2A (5-HT2A ) receptor agonist that is used recreationally worldwide. "( Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects.
Dolder, PC; Kratschmar, DV; Liakoni, E; Liechti, ME; Odermatt, A; Rentsch, KM; Schmid, Y; Strajhar, P, 2016
)
2.22
"Lysergic acid diethylamide (LSD) is a non-selective serotonin-receptor agonist that was first synthesized in 1938 and identified as (potently) psychoactive in 1943. "( Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution.
Bolstridge, M; Bullmore, E; Carhart-Harris, R; Crossley, N; Feilding, A; Kaelen, M; Laufs, H; Leech, R; McGonigle, J; Murphy, K; Muthukumaraswamy, SD; Nutt, DJ; Orban, C; Roseman, L; Tagliazucchi, E; Williams, T, 2016
)
1.88
"Lysergic acid diethylamide (LSD) is a semi-synthetic hallucinogen that has gained popularity as a recreational drug and has been investigated as an adjunct to psychotherapy. "( Development and validation of an ultra-fast and sensitive microflow liquid chromatography-tandem mass spectrometry (MFLC-MS/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in huma
Eisenbeiss, L; Kraemer, T; Liechti, ME; Poetzsch, M; Schmid, Y; Steuer, AE; Stock, L, 2017
)
1.9
"LSD (lysergic acid diethylamide) is a model psychedelic drug used to study mechanism underlying the effects induced by hallucinogens. "( Disrupted integration of sensory stimuli with information about the movement of the body as a mechanism explaining LSD-induced experience.
Juszczak, GR, 2017
)
0.97
"Lysergic acid diethylamide (LSD) is a potent hallucinogenic drug that strongly affects animal and human behavior. "( Characterization of behavioral and endocrine effects of LSD on zebrafish.
Cachat, J; Chung, KM; Dileo, J; Elegante, M; Elkhayat, S; Gaikwad, S; Gilder, T; Grossman, L; Kalueff, AV; Stewart, A; Suciu, C; Tan, J; Utterback, E; Wong, K; Wu, N, 2010
)
1.8
"Lysergic acid diethylamide (LSD) is a potent hallucinogen, active at very low dosage and its determination in body fluids in a forensic context may present some difficulties, even more so in hair. "( LSD in pubic hair in a fatality.
Bargel, S; Gaulier, JM; Lachâtre, G; Lamballais, F; Maublanc, J, 2012
)
1.82
"Lysergic acid diethylamide (LSD) is a psychoactive drug that transiently alters human perception, behavior, and mood at extremely low doses. "( Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration.
Garcia, EE; Nichols, CD; Sanders-Bush, E, 2003
)
2
"Lysergic Acid Diethylamide (LSD) is a hallucinogenic drug that received considerable attention in the 1960's and early 1970's. "( LSD use and flashbacks in alcoholic patients.
Batzer, W; Brown, C; Ditzler, T, 1999
)
1.75
"lsd (lysergic acid diethylamide) is a powerful bio-active substance related to serotonin in structure. "( The LSD syndrome. A review.
Eveloff, HH, 1968
)
0.76

Effects

Lysergic acid diethylamide (LSD) has agonist activity at various serotonin (5-HT) and dopamine receptors. 3,4-methylenedioxymethamphetamine (MDMA) has been used effectively to treat post-traumatic stress disorder.

ExcerptReferenceRelevance
"Lysergic acid diethylamide (LSD) has a history of use as a psychotherapeutic aid in the treatment of mood disorders and addiction, and it was also explored as an enhancer of mind control."( LSD enhances suggestibility in healthy volunteers.
Bolstridge, M; Carhart-Harris, RL; Feilding, A; Kaelen, M; Nutt, DJ; Whalley, MG, 2015
)
1.86
"Lysergic acid diethylamide has been found to have anxiolytic effects, whereas 3,4-methylenedioxymethamphetamine (MDMA) has been used effectively to treat post-traumatic stress disorder (PTSD), with Phase III clinical trial evidence."( Psychedelic medicines for mood disorders: current evidence and clinical considerations.
Day, K; Galvão-Coelho, NL; Perkins, D; Pinzon Rubiano, D; Sarris, J, 2022
)
1.44
"Lysergic acid diethylamide (LSD) has been shown to alter social processing and therefore provides the unique opportunity to investigate the role of the 5-HT"( LSD-induced increases in social adaptation to opinions similar to one's own are associated with stimulation of serotonin receptors.
Duerler, P; Preller, KH; Schilbach, L; Stämpfli, P; Vollenweider, FX, 2020
)
1.28
"Lysergic acid diethylamide (LSD) has agonist activity at various serotonin (5-HT) and dopamine receptors. "( Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor.
Adkinson, BD; Anticevic, A; Burt, JB; Ji, JL; Krystal, JH; Murray, JD; Preller, KH; Repovs, G; Schleifer, CH; Seifritz, E; Stämpfli, P; Vollenweider, FX, 2018
)
1.92
"Lysergic acid diethylamide (LSD) has a history of use as a psychotherapeutic aid in the treatment of mood disorders and addiction, and it was also explored as an enhancer of mind control."( LSD enhances suggestibility in healthy volunteers.
Bolstridge, M; Carhart-Harris, RL; Feilding, A; Kaelen, M; Nutt, DJ; Whalley, MG, 2015
)
1.86

Actions

ExcerptReferenceRelevance
"D-lysergic acid diethylamide (LSD) displays (1) the phenylethylamine pattern present in mescaline, cyclazocine and catecholamines and (2) the 4-substituted tryptamine structure of psilocybin which is a serotonin analog. "( Therapeutic usefulness of hallucinogenic drugs as a function of their chemical structure.
Fischer, R; Goldman, H, 1975
)
0.98

Toxicity

ExcerptReferenceRelevance
" However, the study could not be continued due to severe adverse effects in 3 of 4 subjects, such as cardiovascular dysregulation in two and a psychosis like state in one subject."( Variable adverse effects in subjects after ingestion of equal doses of Argyreia nervosa seeds.
Kremer, C; Paulke, A; Toennes, SW; Wunder, C, 2012
)
0.38
"2, with no acute or chronic adverse effects persisting beyond 1 day after treatment or treatment-related serious adverse events."( Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
Brenneisen, R; Doblin, R; Gasser, P; Holstein, D; Michel, Y; Passie, T; Yazar-Klosinski, B, 2014
)
0.71
" Although several pharmacological treatments are available, they are not effective for a significant proportion of patients and are associated with several adverse reactions."( Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Alcázar-Córcoles, MÁ; Bouso, JC; Dos Santos, RG; Hallak, JEC, 2018
)
0.48
" Based on these reports, using a psychedelic in the microdose range (10 micrograms) every three days was determined to be safe across a wide variety of individuals and conditions."( Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration.
Fadiman, J; Korb, S,
)
0.13
" LSD was well tolerated, and the frequency of adverse events was no higher than for placebo."( Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.
Carhart-Harris, RL; Family, N; Goble, DJ; Krediet, E; Maillet, EL; Nichols, CD; Raz, S; Williams, LTJ; Williams, TM, 2020
)
0.79
" We investigated subjective effects (self-rated any drug effect, good drug effect, bad drug effect, and anxiety), blood pressure, heart rate, body temperature, duration of the acute LSD response, acute (12 h) and subacute (24 h) adverse effects, reports of flashbacks, and liver and kidney function before and after the studies."( Safety pharmacology of acute LSD administration in healthy subjects.
Caluori, TV; Holze, F; Liechti, ME; Vizeli, P, 2022
)
0.72
"LSD dose-dependently increased subjective, physiologic, and adverse effects."( Safety pharmacology of acute LSD administration in healthy subjects.
Caluori, TV; Holze, F; Liechti, ME; Vizeli, P, 2022
)
0.72
"The single-dose administration of LSD is safe in regard to acute psychological and physical harm in healthy subjects in a controlled research setting."( Safety pharmacology of acute LSD administration in healthy subjects.
Caluori, TV; Holze, F; Liechti, ME; Vizeli, P, 2022
)
0.72
" We explore the evidence base for these adverse effects to elucidate which of these harms are based largely on anecdotes versus those that stand up to current scientific scrutiny."( Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.
Aday, J; Neill, JC; Nutt, DJ; Salam, I; Schlag, AK, 2022
)
0.72
"Our review shows that medical risks are often minimal, and that many - albeit not all - of the persistent negative perceptions of psychological risks are unsupported by the currently available scientific evidence, with the majority of reported adverse effects not being observed in a regulated and/or medical context."( Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.
Aday, J; Neill, JC; Nutt, DJ; Salam, I; Schlag, AK, 2022
)
0.72
" There were no serious adverse events."( Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study.
Family, N; Hendricks, PS; Krediet, E; Luke, D; Maillet, EL; Raz, S; Williams, LT, 2022
)
0.72
"In the current novel intervention paradigm, 50, 75, and 100 µg LSD are tolerable with favourable safety profiles in healthy adults, only mild adverse events during the day of drug administration, and mystical-type subjective experiences."( Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study.
Family, N; Hendricks, PS; Krediet, E; Luke, D; Maillet, EL; Raz, S; Williams, LT, 2022
)
0.72
"Most participants felt safe throughout the study, with a minority reporting concerns related to having a challenging experience that diminished over time."( Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a proof-of-concept study.
Copes, H; Family, N; Hendricks, PS; Luke, D; Raz, S; Williams, LT, 2022
)
0.95
"We have analyzed all randomized, double-blind, and controlled trials that assessed the antidepressant effects of psilocybin and LSD in clinical populations to date, taking special attention to adverse events (AEs) related to their use."( Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.
Bouso Saiz, JC; Dos Santos, RG; Hallak, JEC; Rossi, GN, 2022
)
0.72
" Before psychedelics become registered medicines, it is important to know the full range of adverse events (AEs) for making balanced treatment decisions."( Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
Breeksema, JJ; Kamphuis, J; Kuin, BW; Schoevers, RA; van den Brink, W; Vermetten, E, 2022
)
0.72
" Adverse events associated with psychedelics were reported as mild and transient."( A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.
Blumberger, DM; Castle, DJ; Husain, MI; Ledwos, N; McIntyre, RS; Mulsant, BH; Rosenblat, JD,
)
0.13
" Psychedelics are generally considered to be physiologically safe with low toxicity and low addictive potential."( Cardiovascular safety of psychedelic medicine: current status and future directions.
Wsół, A, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
"This article outlines the main pharmacokinetic and toxicokinetic parameters of selected addicting compounds often being abused."( [Pharmacokinetic and toxicokinetic parameters of some drugs of abuse].
Panas, M, 2001
)
0.31
"We characterized the pharmacokinetic profile, pharmacokinetic-pharmacodynamic relationship, and urine recovery of lysergic acid diethylamide and its main metabolite after administration of a single oral dose of lysergic acid diethylamide (200 μg) in 8 male and 8 female healthy subjects."( Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans.
Dolder, PC; Haschke, M; Liechti, ME; Rentsch, KM; Schmid, Y, 2015
)
0.63
"We analyzed pharmacokinetic data from two published placebo-controlled, double-blind, cross-over studies using oral administration of LSD 100 and 200 µg in 24 and 16 subjects, respectively."( Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.
Dolder, PC; Hammann, F; Kraemer, T; Liechti, ME; Rentsch, KM; Schmid, Y; Steuer, AE, 2017
)
0.72
"The present pharmacokinetic data are important for the evaluation of clinical study findings (e."( Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.
Dolder, PC; Hammann, F; Kraemer, T; Liechti, ME; Rentsch, KM; Schmid, Y; Steuer, AE, 2017
)
0.72
" In the current paper, we present safety, tolerability, pharmacokinetics, and pharmacodynamic measures that relate to safety, tolerability, and dose response."( Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.
Carhart-Harris, RL; Family, N; Goble, DJ; Krediet, E; Maillet, EL; Nichols, CD; Raz, S; Williams, LTJ; Williams, TM, 2020
)
0.79
" Pharmacokinetic parameters were determined using compartmental modeling."( Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants.
Dolder, PC; Duthaler, U; Feilding, A; Holze, F; Hutten, NRPW; Kuypers, KPC; Liechti, ME; Mason, NL; Ramaekers, JG; Theunissen, EL, 2021
)
0.89
" These findings indicate that genetic polymorphisms of CYP2D6 significantly influence the pharmacokinetic and subjective effects of LSD."( Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis.
Dolder, PC; Holze, F; Liechti, ME; Schmid, Y; Straumann, I; Vizeli, P, 2021
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
" Herein, we used MIL-101(Cr) as a solid-phase extraction packing material combined with fast detection of direct analysis in real time mass spectrometry (DART-MS) for the analysis of triazine herbicides."( Solid-phase extraction with the metal-organic framework MIL-101(Cr) combined with direct analysis in real time mass spectrometry for the fast analysis of triazine herbicides.
Bai, Y; Chang, C; Li, X; Liu, H; Wang, X; Xing, J; Yan, X, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Lysergic acid diethylamide (LSD) is a potent hallucinogen, active at very low dosage. Its determination in body fluids in a forensic context may present some difficulties, even more so in hair.

ExcerptRelevanceReference
"In the course of examining the complete dose-response relationship for the behavioral effects of LSD in the cat, we discovered that, in addition to large increases in investigatory and hallucinatory-like responses, two behaviors, not previously reported, are emitted with a high probability under LSD."( Behavioral effects of LSD in the cat: proposal of an animal behavior model for studying the actions of hallucinogenic drugs.
Jacobs, BL; Stern, WC; Trulson, ME, 1977
)
0.26
", total dose) did not modify the dose-response curve to 5-HT except for the lowest dose."( Analysis of the contractile effect of 5-hydroxytryptamine on the isolated posterior communicating artery of the cat.
Gómez, B; Lluch, S; Marco, EJ; Marín, J; Salaices, M, 1979
)
0.26
" The frequency of responding within 800 msec of CS onset or in the 800 msec before shock onset was low (2-3%) and was not affected by any dosage of LSD, indicating that the effects of LSD on acquisition were not due to sensitization, pseudoconditioning or changes in baseline responding."( Effects of LSD on learning as measured by classical conditioning of the rabbit nictitating membrane response.
Gimpl, MP; Gormezano, I; Harvey, JA, 1979
)
0.26
" Delta-THC in a dosage of 1 mg/kg had no effect on avoidance learning."( The effect of delta 9-tetrahydrocannabinol and LSD on the acquisition of an active avoidance response in the rat.
Heer-Carcano, L; Martin, A; Waser, PG, 1976
)
0.26
" to Sprague-Dawley rats on a tolerance dosage schedule (L X 7) were compared with the effects of a single dose of LSD (L X 1) 520 mug/kg or 1040 mug/kg, over a 90 min time course."( Effects of single and multiple dose LSD on endogenous levels of brain tyrosine and catecholamines.
Boggan, WO; Freedman, DX; Smith, RC, 1975
)
0.25
" A dose-response curve for LSD, obtained by tests for lever choice after injections of 10, 20, 30, 40, 50, and 60 mug/kg, indicated that 10 mug/kg produced only 30% responding on the LSD lever."( Behaviorally induced sensitivity to the discriminable properties of LSD.
Appel, JB; Greenberg, I; Kuhn, DM, 1975
)
0.25
" Animals injected with either dosage of LSD had smaller body weights than controls and tail length was significantly reduced in the high dosage group, plasma levels of growth hormone (GH) were decreased in the high dosage group, and pituitary levels in the low dosage group."( Endocrine effects of chronic administration of psychoactive drugs to prepubertal male rats. II. LSD.
Collu, R; Ducharme, JR; Leboeuf, G; Letarte, J, 1975
)
0.25
" Prolonged use of benzodiazepines can lead to drug dependence; successful withdrawal involves gradual dosage reduction."( Pharmacologic considerations in the treatment of substance abuse.
Skinner, MH; Thompson, DA, 1992
)
0.28
" In the latter assay, both enantiomers of 6 had identical potencies, but their dose-response curves were not parallel."( Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA).
Frescas, SP; Johnson, MP; Nichols, DE; Oberlender, R, 1991
)
0.28
"A dosage regimen of lysergic acid diethylamide (LSD) that reliably produces behavioral tolerance in rats was evaluated for effects on neurotransmitter receptor binding in rat brain using a variety of radioligands selective for amine receptor subtypes."( Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain.
Buckholtz, NS; Freedman, DX; Potter, WZ; Zhou, DF, 1990
)
2.05
"8 mg/kg, was fatal in 4 of 5 MH-susceptible pigs, whereas pigs injected with this dosage after pretreatment with ketanserin (0."( Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: stimulation of 5-HT2 receptors induces malignant hyperthermia.
Bickhardt, K; Fredow, G; Ganter, M; Löscher, W; Witte, U, 1990
)
0.28
" Dose-response tests with LSD and LHM indicated that, as dose increased, the per cent of responding on the lever associated with the particular training drug also increased; little or no cross-transfer occurred between LSD and LHM."( Differentiation between the stimulus effects of (+)-lysergic acid diethylamide and lisuride using a three-choice, drug discrimination procedure.
Appel, JB; Callahan, PM, 1990
)
0.53
" Dose-response data were obtained from extracellular records of the firing of DRN neurons recorded in midbrain slices perfused with artificial cerebral spinal fluid containing varying concentrations of the drugs investigated."( Electrophysiological and biochemical characterization of the development of alpha 1-adrenergic and 5-HT1 receptors associated with dorsal raphe neurons.
Gallager, DW; Smith, DA, 1989
)
0.28
" BOL caused concentration-dependent parallel rightward shifts of the 5-HT dose-response curve in untreated aortas but, in addition, caused a marked reduction of maximal response in aortas pretreated with benextramine to inactivate alpha adrenoceptors."( Evidence for allosteric blockade of serotonergic receptors in rabbit thoracic aorta.
Purdy, RE; Xu, Z, 1989
)
0.28
" Isolated aortic rings were mounted in tissue baths for the measurement of isometric contraction and 5-HT dose-response curves were obtained in the presence and absence of receptor antagonists."( Receptors for 5-hydroxytryptamine in rabbit blood vessels: activation of alpha adrenoceptors in rabbit thoracic aorta.
Murray, DL; Purdy, RE; Stupecky, GL, 1987
)
0.27
" Low microiontophoretic currents of ipsapirone and LY 165163 were also effective in suppressing spontaneous firing; dose-response relationships for the 5-HT1A compounds were indistinguishable from that of 5-HT itself."( Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists.
Aghajanian, GK; Sprouse, JS, 1987
)
0.27
" Infusion of DOM into the lateral habenular nuclei produced a biphasic dose-response curve."( The effects of intracranial administration of hallucinogens on operant behavior in the rat. II. 2,5-Dimethoxy-4-methylamphetamine (DOM).
Mokler, DJ; Rech, RH; Sherman, LC; Stoudt, KW, 1987
)
0.27
" The dose-response curves for the phenethylamine hallucinogens were shifted significantly to the right and to a greater degree than were those for the indolealkylamine hallucinogens."( The 5HT2 antagonist pirenperone reverses disruption of FR-40 by hallucinogenic drugs.
Mokler, DJ; Rech, RH; Stoudt, KW, 1985
)
0.27
" A dose-response curve for each of the compounds in the series was generated."( Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives.
Hoffman, AJ; Nichols, DE, 1985
)
0.27
" In both situations, lisuride exhibited a biphasic dose-response curve for horizontal locomotion (low dose suppression and high dose enhancement), while rearing was significantly reduced at all doses."( Patterns of exploration in rats distinguish lisuride from lysergic acid diethylamide.
Adams, LM; Geyer, MA, 1985
)
0.51
" There did not appear to be a dose-response relation."( LSD and genetic damage.
Dishotsky, NI; Lipscomb, WR; Loughman, WD; Mogar, RE, 1971
)
0.25
" Based on the analysis of LSD dosage and the time course of the LSD-induced brain polysome shift, it was found that free polysomes were more sensitive to the drug than the membrane-bound polysome fraction."( Comparison of the effect of intravenous administration of d-lysergic acid diethylamide on free and membrane-bound polysomes in the rabbit brain.
Brown, IR; Heikkila, JJ, 1981
)
0.5
" Comparisons were made on the basis of dose-response relationships."( Anorexia and hyperphagia produced by five pharmacologic classes of hallucinogens.
Morton, EC; Vaupel, DB, 1982
)
0.26
" All drugs have been shown to inhibit specifically the locomotor activity potentiating effect of LSD in a low dosage range (0."( Effects of atypical antidepressants on LSD potentiated apomorphine hypermotility in rats.
Fink, H; Gold, R; Morgenstern, R, 1980
)
0.26
" The DOM dose-response pattern for decrease in reinforcers was shifted to the greatest degree by metergoline, followed by pizotifen and cinanserin (ED50 values: 26."( Blockade of the behavioral effects of lysergic acid diethylamide, 2,5-dimethoxy-4-methylamphetamine, quipazine and lisuride by 5-hydroxytryptamine antagonists.
Commissaris, RL; Mokler, DJ; Rech, RH; Warner, MR, 1983
)
0.54
" A dose-response curve was generated for each antagonist and an ID50 value (dose that inhibits responding to 50% on the quipazine lever) was determined by log-logit analysis."( Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites.
Barrett, RJ; Friedman, RL; Sanders-Bush, E, 1984
)
0.27
" The electrophysiologic response produced by each drug correlates well in dosage and time-course with their reported behavioral effects."( Acute and chronic effects of LSD and 5-MeODMT on raphe-evoked dorsal root potentials in the cat.
Larson, AA, 1984
)
0.27
" The dose-response curve for this discrimination was orderly with an ED50 of about one-half of the training dose (0."( A neuropharmacological analysis of the discriminative stimulus properties of fenfluramine.
Appel, JB; White, FJ, 1981
)
0.26
" Dose-response tests revealed that the three LSD cues were specific to the dose used during training and that, as the training dose declined, the slope of the LSD dose-response curve became less steep."( Training dose as a factor in LSD-saline discrimination.
Appel, JB; White, FJ, 1982
)
0.26
" Dose-response and time-response curves were obtained."( Psilocybin as a discriminative stimulus: lack of specificity in an animal behavior model for 'hallucinogens'.
Appel, JB; Koerner, J, 1982
)
0.26
" Furthermore, combinations of the hallucinogens interact with potentiation to cause FR-40 pausing, whereas a variety of non-hallucinogenic psychoactive drugs failed to shift the dose-response patterns of pausing for DOM or LSD."( Neurotransmitter basis of the behavioral effects of hallucinogens.
Commissaris, RL; Rech, RH, 1982
)
0.26
" Dose-response tests showed that the three LHM cues were specific to the dose used during training and the dose-response curve became more steep as the training dose increased."( The role of dopamine and serotonin in the discriminative stimulus effects of lisuride.
Appel, JB; White, FJ, 1982
)
0.26
" After stable discrimination performances were attained (greater than 85%) in each group, dose-response generalizations between the two groups of animals were examined."( Comparative discriminative stimulus effects of 5-methoxy-N,N-dimethyltryptamine and LSD.
Glennon, RA; Rosecrans, JA; Young, R, 1982
)
0.26
" However, since the dose-response curves for quipazine during the day and night are virtually identical, we hypothesize that the nighttime 5-HT receptor is a 5-HT1-like receptor."( Serotonin and the mammalian circadian system: I. In vitro phase shifts by serotonergic agonists and antagonists.
Dean, RR; Edgar, DM; Heller, HC; Miller, JD; Prosser, RA, 1993
)
0.29
" Coadministration of clonidine with LSD produced a leftward shift of the dose-response relationship of LSD without a significant change in the slope of the dose-response line."( Complex stimulus properties of LSD: a drug discrimination study with alpha 2-adrenoceptor agonists and antagonists.
Marona-Lewicka, D; Nichols, DE, 1995
)
0.29
" Eight healthy subjects were given fluvoxamine in increasing dosage from 25 mg/day to 200 mg/day during 4 weeks, and serum sodium and serum prolactin concentrations were obtained weekly."( The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status.
Mjorndal, T; Spigset, O, 1997
)
0.3
" In order to investigate whether treatment with a selective serotonin reuptake inhibitor affects platelet 5-HT2A receptors, we have studied platelet [3H]lysergic acid diethylamide ([3H]LSD) binding in healthy subjects treated with fluvoxamine in increasing dosage once weekly for 4 weeks."( Effect of fluvoxamine on platelet 5-HT2A receptors as studied by [3H]lysergic acid diethylamide ([3H]LSD) binding in healthy volunteers.
Mjörndal, T; Spigset, O, 1997
)
0.73
" Also, the higher gene dosage resulting from multiple insertions of the expression cassette led to an improvement in production by a factor of two for both receptors."( Comparative biochemical and pharmacological characterization of the mouse 5HT5A 5-hydroxytryptamine receptor and the human beta2-adrenergic receptor produced in the methylotrophic yeast Pichia pastoris.
Haase, W; Michel, H; Reiländer, H; Weiss, HM, 1998
)
0.3
" Dose-response curves were obtained for the effects of several 5-HT2 receptor antagonists on response magnitude."( Effect of 5-HT2 receptor antagonists on a cranial nerve reflex in the rabbit: evidence for inverse agonism.
Harvey, JA; Hood, H; Romano, AG; Welsh, SE, 1999
)
0.3
" Additional experiments using clinical samples in which two subjects were dosed with LSD support the conclusion that analysis for 2-oxo-3-hydroxy-LSD can permit identification of LSD users for a longer period following ingestion than analysis for the parent drug."( Quantitative determination of LSD and a major metabolite, 2-oxo-3-hydroxy-LSD, in human urine by solid-phase extraction and gas chromatography-tandem mass spectrometry.
Eades, DM; Foltz, RL; Liu, S; Percey, SE; Reuschel, SA, 1999
)
0.3
" This recovery of firing was associated with a 3-fold shift to the right of the dose-response curve of the effect of the 5-HT autoreceptor agonist lysergic acid diethylamide on the firing activity of 5-HT neurons, indicating a desensitization of somatodendritic 5-HT1A autoreceptors."( Effect of sustained administration of the 5-HT1A receptor agonist flesinoxan on rat 5-HT neurotransmission.
Blier, P; de Montigny, C; Haddjeri, N; Ortemann, C, 1999
)
0.5
" The article shows the usual dosage and "therapeutic", toxic and fatal concentrations."( [Pharmacokinetic and toxicokinetic parameters of some drugs of abuse].
Panas, M, 2001
)
0.31
" The dose-response relationship indicated that percent drug lever responding was dose-dependent."( Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+/-)DOI] in C57BL/6J mice.
Barrett, RJ; Sanders-Bush, E; Smith, RL, 2003
)
0.32
" Time-course and dose-response relationships for (-)-DOM and LSD administered intracerebroventricularly were established."( Characterization of the discriminative stimulus properties of centrally administered (-)-DOM and LSD.
Doat, MM; Rabin, RA; Winter, JC, 2003
)
0.32
" Dose-response studies show two classes of expression; gene expression maximally stimulated at lower doses, versus gene expression that continues to rise at the higher doses."( Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration.
Garcia, EE; Nichols, CD; Sanders-Bush, E, 2003
)
0.56
" The dosage of LSD employed was 25 to 2000 micrograms intramuscularly per session for from one to 10 sessions."( THE USE OF LYSERGIC ACID DIETHYLAMIDE (LSD) IN PSYCHOTHERAPY.
BAKER, EF, 1964
)
0.63
" In a series of follow-up studies using hallucinogen-induced head twitch response and phencyclidine-induced hyperlocomotion, it was additionally discovered that the repeated dosing regimen required for discrimination training attenuated the behavioral effects of the mGlu2/3 receptor agonist LY379268."( Chronic phenethylamine hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor agonist.
Benneyworth, MA; Sanders-Bush, E; Smith, RL, 2008
)
0.35
" In combination tests, both agonists shifted the dose-response curve of LSD leftward, most potently for the LSD-90 cue."( Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI.
Chemel, BR; Marona-Lewicka, D; Nichols, DE, 2009
)
0.35
"Lysergic acid diethylamide (LSD) is a potent hallucinogen, active at very low dosage and its determination in body fluids in a forensic context may present some difficulties, even more so in hair."( LSD in pubic hair in a fatality.
Bargel, S; Gaulier, JM; Lachâtre, G; Lamballais, F; Maublanc, J, 2012
)
1.82
" Finally, a screening level risk assessment that combines the measured environmental concentrations (MECs) with dose-response data to estimate Hazard Quotients (HQs) for the compounds studied is also presented."( Drugs of abuse and benzodiazepines in the Madrid Region (Central Spain): seasonal variation in river waters, occurrence in tap water and potential environmental and human risk.
Barceló, D; González-Alonso, S; López de Alda, M; Mastroianni, N; Mendoza, A; Rodríguez-Gil, JL; Valcárcel, Y, 2014
)
0.4
" There were no significant interactions between LSD treatment and Sert gene dosage in any of the behavioral domains measured."( Effects of LSD on grooming behavior in serotonin transporter heterozygous (Sert⁺/⁻) mice.
Kalueff, AV; Kyzar, EJ; Stewart, AM, 2016
)
0.43
"Primary outcome measures were (i) the percentage of samples purchased on-line and (ii) the chemical purity of powders (or dosage per tablet); adulteration; and the price per gram, blotter or tablet of drugs bought on-line compared with drugs bought off-line."( Purity, adulteration and price of drugs bought on-line versus off-line in the Netherlands.
Brunt, TM; van der Gouwe, D; van der Pol, P; van Laar, M, 2017
)
0.46
" The present study addressed this gap by surveying psychedelic users about their experience with microdosing including their dosing schedule, motivation, and potential experienced negative effects."( Motives and Side-Effects of Microdosing With Psychedelics Among Users.
Dolder, PC; Hutten, NRPW; Kuypers, KPC; Mason, NL, 2019
)
0.51
" We examined motivations, dosing practices, and perceived benefits and limitations of microdosing."( Psychedelic Microdosing: A Subreddit Analysis.
Amada, N; Jungaberle, H; Lea, T,
)
0.13
" This paper examines microdosing motivations, dosing practices, perceived short-term benefits, unwanted effects, and harm reduction practices."( Microdosing psychedelics: Motivations, subjective effects and harm reduction.
Amada, N; Jungaberle, H; Klein, M; Lea, T; Schecke, H, 2020
)
0.56
" The third report indicates that intranasal ingestion of 550 times the normal recreational dosage of LSD was not fatal and had positive effects on pain levels and subsequent morphine withdrawal."( LSD Overdoses: Three Case Reports.
Haden, M; Woods, B, 2020
)
0.56
" In contrast to the primary hypothesis, psychedelics had no long-lasting effects on the ADE in male and female rats, neither when administered in a high dosage regime that is comparable to the one used in clinical studies, nor in a chronic microdosing scheme."( Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse.
Güngör, C; Meinhardt, MW; Mertens, LJ; Skorodumov, I; Spanagel, R, 2020
)
0.56
" This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance."( Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study.
Dolder, PC; Feilding, A; Holze, F; Hutten, NRPW; Kuypers, KPC; Liechti, ME; Mason, NL; Ramaekers, JG; Theunissen, EL, 2020
)
0.56
"We employed in vivo extracellular single-unit recordings in anesthetized adult male mice to investigate the dose-response effects of cumulative LSD doses (5-160 µg/kg, intraperitoneal) upon reticular thalamus GABAergic neurons, thalamocortical relay neurons of the mediodorsal thalamus, and pyramidal neurons of the infralimbic prefrontal cortex."( Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: An in vivo electrophysiology study in male mice.
Comai, S; De Gregorio, D; Gobbi, G; Inserra, A; Lopez-Canul, MG; Rezai, T, 2021
)
2.06
"LSD decreased spontaneous firing and burst-firing activity in 50% of the recorded reticular thalamus neurons in a dose-response fashion starting at 10 µg/kg."( Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: An in vivo electrophysiology study in male mice.
Comai, S; De Gregorio, D; Gobbi, G; Inserra, A; Lopez-Canul, MG; Rezai, T, 2021
)
2.06
"This study will rigorously examine the claims presented in the microdosing grey literature by pairing a comparable dosing protocol with objective measures."( MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers.
Evans, W; Hoeh, N; Lambrecht, I; Menkes, D; Murphy, RJ; Muthukumaraswamy, S; Ponton, R; Ram, S; Reynolds, L; Sumner, RL; Sundram, F, 2021
)
0.62
", choosing the right patients for these therapies), (3) the dosing preparation sessions, (4) the assisted dosing sessions as well as after-care procedures such as (5) psychological integration and (6) supporting the development of structured patient communities."( The Potential Role of Psychedelic Drugs in Mental Health Care of the Future.
Gründer, G; Jungaberle, H, 2021
)
0.62
" The dose-response curves for the proportions of subjects with a certain amount of a subjective effect were steeper and reached a higher maximum for positive acute subjective effects compared with negative acute subjective effects."( Safety pharmacology of acute LSD administration in healthy subjects.
Caluori, TV; Holze, F; Liechti, ME; Vizeli, P, 2022
)
0.72
"To determine how differences in the type of psychedelic agent used and the number of dosing sessions administered affect subjects' depression and anxiety outcomes and adverse drug reactions (ADR)."( Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
Leger, RF; Unterwald, EM, 2022
)
0.72
" Controlled study data on dosing using well-characterized pharmaceutical formulations of the substances are scarce."( Dosing Psychedelics and MDMA.
Holze, F; Liechti, ME, 2022
)
0.72
" The reported lasting clinical effects after limited dosing with psychedelics present a novel means for disease management, but considerable further study will be required to address disease-specific treatments, uncover mechanism(s) of action, and verify safety."( Psychedelics in the Treatment of Headache and Chronic Pain Disorders.
Schindler, EAD, 2022
)
0.72
" In addition, this article considers the effects that macro- and microdoses have on behavior and psychopathology in light of their dosage characteristics and contexts of use."( Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives.
Kaypak, AC; Raz, A, 2022
)
0.72
" The detection of LSD is problematic because of the low dosage taken by users, light and heat sensitivity of the analyte and the lack of efficient analytical methods."( Quantitative Analysis of Lysergic Acid Diethylamide and Metabolite in Urine by Automated Extraction and Liquid Chromatography-Tandem Mass Spectrometry.
Brown, J; Heine, K; Karschner, EL; Patton, AL; Sartori, DA; Walterscheid, JP, 2023
)
1.21
" Randomized controlled trials have failed to support these claims, but the laboratory-based dosing in trials conducted to date may have limited ecological validity."( Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial.
Cavadino, A; Evans, W; Forsyth, A; Godfrey, K; Hoeh, NR; Krishnamurthy Naga, V; Menkes, DB; Murphy, RJ; Muthukumaraswamy, S; Ponton, R; Ram, S; Smith, T; Sumner, R, 2023
)
1.17
" Here we present the first meta-analysis establishing dose-response relationship estimates of the altered states of consciousness induced by LSD."( Dose-response relationships of LSD-induced subjective experiences in humans.
Hirschfeld, T; Majić, T; Prugger, J; Schmidt, TT, 2023
)
0.91
" In reviewing these topics, we identify three knowledge gaps as areas of future inquiry: sex differences, oral dosing rather than injection, and chronic dosing regimens."( Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
Ezeaka, UC; Kim, HJJ; Laprairie, RB, 2023
)
1.15
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (12 Product(s))

Product Categories

Product CategoryProducts
Food & Beverages11
Active Lifestyle & Fitness1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
HomeFree Gluten Free Mini Cookies Chocolate Chip -- 5 ozHomeFreeFood & Beverageschocolate chips, baking soda, cane sugar2024-11-29 10:47:42
Larabar Gluten Free Fruit & Nut Bar Chocolate Chip Brownie -- 16 BarsLarabarFood & BeveragesVitamin C, Vitamin E, Vitamin E, chocolate chips, Vitamin A2024-11-29 10:47:42
Larabar Gluten Free Fruit & Nut Bar Chocolate Chip Cookie Dough -- 16 BarsLarabarFood & Beverageschocolate chips2024-11-29 10:47:42
Larabar Gluten Free Fruit & Nut Bar Mint Chip Brownie -- 16 BarsLarabarFood & BeveragesVitamin C, chocolate chips, Phosphorus, Vitamin A2024-11-29 10:47:42
Miss Jones Brownie Baking Mix Double Chocolate -- 14.67 ozMiss JonesFood & Beverageschocolate chips, baking soda, cane sugar, vanilla2024-11-29 10:47:42
Miss Jones Every Day Cookie Mix Monster -- 10.57 ozMiss JonesFood & Beveragesbeta carotene, chocolate chips, baking soda, sugar, vanilla2024-11-29 10:47:42
Miss Jones EveryDay Delicious Cookie Mix Chocolate Chip -- 13 ozMiss JonesFood & Beverageschocolate chips, baking soda, sugar, vanilla2024-11-29 10:47:42
My Cookie Dealer Protein Cookies Chocolate Candy Ganache -- 12 CookiesMy Cookie DealerActive Lifestyle & Fitnessred 40, calcium acetate, dextrin, lactose, chocolate chips, sodium benzoate, sodium bicarbonate, sodium propionate, sugar, yellow 5 lake2024-11-29 10:47:42
Over Easy Oat Bar Soft & Chewy Soy Free Gluten Free Peanut Butter Dark Chocolate -- 12 BarsOver EasyFood & Beverageschocolate chips2024-11-29 10:47:42
Siete Cookies Grain Free - Gluten Free Vegan Chocolate Chip -- 4.5 ozSieteFood & Beverageschocolate chips, baking soda, cane sugar2024-11-29 10:47:42
Three Wishes Granola Gluten Free Grain Free Chocolate Almond -- 8 ozThree WishesFood & Beverageserythritol, chocolate chips2024-11-29 10:47:42
Zing Plant-Based Bar Oatmeal Chocolate Chip -- 12 BarsZingFood & Beverageschocolate chips, allulose2024-11-29 10:47:42

Roles (3)

RoleDescription
hallucinogenDrugs capable of inducing illusions, hallucinations, delusions, paranoid ideations and other alterations of mood and thinking.
serotonergic agonistAn agent that has an affinity for serotonin receptors and is able to mimic the effects of serotonin by stimulating the physiologic activity at the cell receptors. Serotonin agonists are used as antidepressants, anxiolytics, and in the treatment of migraine disorders.
dopamine agonistA drug that binds to and activates dopamine receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
ergoline alkaloidOne of a class of naturally occurring alkaloids with a structure based on that of ergoline.
organic heterotetracyclic compound
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (52)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency78.93050.002541.796015,848.9004AID1347395; AID1347397; AID1347398
Fumarate hydrataseHomo sapiens (human)Potency50.11870.00308.794948.0869AID1347053
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency31.25150.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency47.88160.000714.592883.7951AID1259369; AID1259392
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency44.25920.001022.650876.6163AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency82.84880.01237.983543.2770AID1645841
retinoid X nuclear receptor alphaHomo sapiens (human)Potency114.05700.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency86.54100.001530.607315,848.9004AID1224841; AID1224848; AID1224849
pregnane X nuclear receptorHomo sapiens (human)Potency80.03090.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency14.92560.000229.305416,493.5996AID743069; AID743075; AID743077; AID743078; AID743079
GVesicular stomatitis virusPotency82.84880.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency0.92960.00108.379861.1304AID1645840
polyproteinZika virusPotency50.11870.00308.794948.0869AID1347053
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency179.16000.023723.228263.5986AID743222
aryl hydrocarbon receptorHomo sapiens (human)Potency21.39970.000723.06741,258.9301AID743085; AID743122
thyroid stimulating hormone receptorHomo sapiens (human)Potency74.54420.001628.015177.1139AID1224843; AID1224895; AID1259385
Histone H2A.xCricetulus griseus (Chinese hamster)Potency158.48900.039147.5451146.8240AID1224845
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency81.94960.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency63.56850.000627.21521,122.0200AID743202
Interferon betaHomo sapiens (human)Potency82.84880.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency82.84880.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency82.84880.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency2.97290.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency2.97290.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency82.84880.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorHomo sapiens (human)Ki0.74000.00000.66359.5499AID41502
Beta-1 adrenergic receptorHomo sapiens (human)Ki0.14000.00011.33919.9840AID40552
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki0.00120.00010.532610.0000AID3826; AID3854; AID3925
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki0.00460.00020.667710.0000AID267699; AID4761; AID5001; AID5726; AID5738
D(2) dopamine receptorHomo sapiens (human)Ki0.12290.00000.651810.0000AID63247; AID64142
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki0.00360.00010.601710.0000AID267698; AID5001; AID5523; AID5537; AID5546; AID5577
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki0.00510.00010.739610.0000AID3994; AID4044
D(4) dopamine receptorHomo sapiens (human)Ki0.05600.00000.436210.0000AID63846
D(1B) dopamine receptorHomo sapiens (human)Ki0.34000.00030.40177.9000AID64194
Catechol O-methyltransferaseRattus norvegicus (Norway rat)Ki0.00250.00150.00660.0159AID5001
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)Ki0.01000.00030.37088.1600AID6499
5-hydroxytryptamine receptor 1DHomo sapiens (human)Ki0.00390.00010.808710.0000AID4916
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.00330.00000.385510.0000AID408464; AID408465; AID408466; AID408467; AID5421
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.00500.00010.954910.0000AID5650
5-hydroxytryptamine receptor 1EHomo sapiens (human)Ki0.09300.09304.770110.0000AID4971
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki0.00250.00020.590910.0000AID5001
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)Ki0.00580.00000.14803.1800AID6648; AID6666
5-hydroxytryptamine receptor 7Homo sapiens (human)Ki0.00650.00030.380610.0000AID6611; AID6689
Histamine H1 receptorHomo sapiens (human)Ki1.54000.00000.511010.0000AID87691
D(3) dopamine receptorHomo sapiens (human)Ki0.02700.00000.602010.0000AID65784
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.03000.00030.769310.0000AID5829
5-hydroxytryptamine receptor 5AHomo sapiens (human)Ki0.00950.00080.94335.1600AID6499; AID6502
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki0.00660.00020.522910.0000AID6535; AID6574
Sodium-dependent dopamine transporter Homo sapiens (human)Ki0.34000.00021.11158.0280AID64194
DMus musculus (house mouse)Ki0.18000.00040.76232.5300AID61837
Sodium-dependent dopamine transporterMacaca fascicularis (crab-eating macaque)Ki0.34000.34000.34000.3400AID64194
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)EC50 (µMol)0.00980.00010.49294.0000AID267700; AID5466
5-hydroxytryptamine receptor 2AHomo sapiens (human)EC50 (µMol)0.00920.00000.22763.4750AID1865344; AID1865346; AID1865348; AID1865350
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (315)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral fear responseD(4) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(4) dopamine receptorHomo sapiens (human)
response to amphetamineD(4) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
adult locomotory behaviorD(4) dopamine receptorHomo sapiens (human)
positive regulation of sodium:proton antiporter activityD(4) dopamine receptorHomo sapiens (human)
positive regulation of kinase activityD(4) dopamine receptorHomo sapiens (human)
response to histamineD(4) dopamine receptorHomo sapiens (human)
social behaviorD(4) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
fear responseD(4) dopamine receptorHomo sapiens (human)
regulation of circadian rhythmD(4) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(4) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(4) dopamine receptorHomo sapiens (human)
rhythmic processD(4) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(4) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(4) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
inhibitory postsynaptic potentialD(4) dopamine receptorHomo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationD(4) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(4) dopamine receptorHomo sapiens (human)
chemical synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1B) dopamine receptorHomo sapiens (human)
response to amphetamineD(1B) dopamine receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinD(1B) dopamine receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureD(1B) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(1B) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1B) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
chemical synaptic transmissionD(1B) dopamine receptorHomo sapiens (human)
associative learningD(1B) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1B) dopamine receptorHomo sapiens (human)
negative regulation of NAD(P)H oxidase activityD(1B) dopamine receptorHomo sapiens (human)
wound healingD(1B) dopamine receptorHomo sapiens (human)
response to cocaineD(1B) dopamine receptorHomo sapiens (human)
positive regulation of adenylate cyclase activityD(1B) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(1B) dopamine receptorHomo sapiens (human)
regulation of female receptivityD(1B) dopamine receptorHomo sapiens (human)
sensitizationD(1B) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1B) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1B) dopamine receptorHomo sapiens (human)
reactive oxygen species metabolic processD(1B) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1B) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of locomotion5-hydroxytryptamine receptor 1DHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1DHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1EHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1EHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1EHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1EHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1EHomo sapiens (human)
smooth muscle contraction5-hydroxytryptamine receptor 7Homo sapiens (human)
circadian rhythm5-hydroxytryptamine receptor 7Homo sapiens (human)
blood circulation5-hydroxytryptamine receptor 7Homo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 7Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 7Homo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 5AHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 5AHomo sapiens (human)
hippocampus development5-hydroxytryptamine receptor 5AHomo sapiens (human)
response to estradiol5-hydroxytryptamine receptor 5AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 5AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 5AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 5AHomo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (67)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(4) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
protein bindingD(4) dopamine receptorHomo sapiens (human)
potassium channel regulator activityD(4) dopamine receptorHomo sapiens (human)
SH3 domain bindingD(4) dopamine receptorHomo sapiens (human)
dopamine bindingD(4) dopamine receptorHomo sapiens (human)
identical protein bindingD(4) dopamine receptorHomo sapiens (human)
metal ion bindingD(4) dopamine receptorHomo sapiens (human)
epinephrine bindingD(4) dopamine receptorHomo sapiens (human)
norepinephrine bindingD(4) dopamine receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityD(4) dopamine receptorHomo sapiens (human)
neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
serotonin bindingD(4) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1B) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1B) dopamine receptorHomo sapiens (human)
protein bindingD(1B) dopamine receptorHomo sapiens (human)
dopamine bindingD(1B) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1B) dopamine receptorHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor activity5-hydroxytryptamine receptor 1EHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1EHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1EHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1EHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1EHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 5AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 5AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 5AHomo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (72)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
centrosomeD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
membraneD(4) dopamine receptorHomo sapiens (human)
postsynapseD(4) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
dendriteD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(1B) dopamine receptorHomo sapiens (human)
ciliumD(1B) dopamine receptorHomo sapiens (human)
brush border membraneD(1B) dopamine receptorHomo sapiens (human)
synapseD(1B) dopamine receptorHomo sapiens (human)
ciliary membraneD(1B) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1B) dopamine receptorHomo sapiens (human)
plasma membraneD(1B) dopamine receptorHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1DHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1EHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1EHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1EHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1EHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
trans-Golgi network membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
synapse5-hydroxytryptamine receptor 7Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 7Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 5AHomo sapiens (human)
perikaryon5-hydroxytryptamine receptor 5AHomo sapiens (human)
postsynaptic specialization membrane5-hydroxytryptamine receptor 5AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 5AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 5AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (212)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID177676Effective concentration required to determined hallucinogen-like activity in LSD-trained rats2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
A novel fluorinated tryptamine with highly potent serotonin 5-HT1A receptor agonist properties.
AID64194Binding affinity towards Dopamine receptor D52002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID5421Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
A novel ergot alkaloid as a 5-HT(1A) inhibitor produced by Dicyma sp.
AID190087Tested for stimulus generation in rats trained to discriminate LSD from saline at a dose 0.093(umol/kg) (number of animals = 8)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID1865351Agonist activity at human 5HT2A S159A mutant transfected in HEK293T cells assessed as mini Galphaq recruitment measured for 2 hrs by luminescent assay relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT
AID170051Number of rats scored LSD correct/number tested was reported at a dose of 93.0 nM/Kg using 2-lever drug discrimination assay; 6/81985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives.
AID177419Compound was evaluated for the drug discrimination assay and the ED50 (potency) was determined in rats1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Substituent branching in phenethylamine-type hallucinogens: a comparison of 1-[2,5-dimethoxy-4-(2-butyl)phenyl]-2-aminopropane and 1-[2,5-dimethoxy-4-(2-methylpropyl)phenyl]-2-aminopropane.
AID169905Number of rats scored LSD correct/number tested was reported at a dose of 11.5 nM/Kg using 2-lever drug discrimination assay; 0/81985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives.
AID225134Effective dose as nmol/kg after 0.02 mg/kg, 0.046 uM/kg dose (95%CI)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID63846Binding affinity towards Dopamine receptor D42002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID174863Hallucinogenic property was determined in groups of LSD trained rats and percentage of animals disrupted was reported at a dose 0.046(umol/kg) (number of animals = 9)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID5466Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
AID2330285-HT1C selectivity was defined as the ratio between Ki(5-HT2)/Ki(5-HT1C)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity.
AID1865346Agonist activity at human 5HT2A receptor transfected in HEK293T cells assessed as mini Galphaq recruitment measured for 2 hrs by luminescent assay2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT
AID408467Displacement of [3H]INBMeO from human 5HT2A receptor expressed in human HEK293 cells2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.
AID6499Binding affinity for rodent 5-hydroxytryptamine 5A receptor2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
AID41502Binding affinity towards Beta-2 adrenergic receptor2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID57528Evaluated in the two-lever drug discrimination assay in DOI trained rats to assess hallucinogenic-like activity (95% confidence intervals)2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.
AID3612Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane.
AID6535Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
A novel ergot alkaloid as a 5-HT(1A) inhibitor produced by Dicyma sp.
AID192225Percentage of animals emitting >80% of lever presses in rats at 0.04 mg/kg dose1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
AID226145Percentage of rats selecting the drug lever (SDL) after 0.01 mg/kg, 0.023 uM/kg dose2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID175227Percentage of animals failing to emit 50 lever presses within 15 min in rats at 0.08 mg/kg dose1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
AID225131Effective dose in rats as mg/kg after 0.02 mg/kg, 0.046 uM/kg dose (95%CI)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID178017Effective dose for LSD-like behavioral effect in rats1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
AID226144Percentage of rats selecting drug lever (SDL) after 0.04 mg/kg, 0.093 uM/kg dose2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID176658Substitution tests were carried out for the compound in LSD- trained rats dosed with 0.02 mg/kg drug and the binding data was reported1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain.
AID189893Percentage of rats selecting the drug liver at dose of 0.02 mg/kg1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain.
AID1134692Hyperthermic activity in New Zealand rabbit assessed as mean maximum rise in rectal temperature at 0.25 to 21.2 umol/kg administered in marginal ear vein as solution of amine hydrochloride in nonpyrogenic saline relative to l-(2,5-dimethoxy-4-methylphenyl1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Monomethylthio analogues of 1-(2,4,5-trimethoxyphenyl)-2-aminopropane.
AID5577In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
AID178357Compound was tested for hallucinogenic activity in rats at the dose 0.0025 (mg/kg)1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
AID188030Potency in trained rats was determined with relative to reference compound d-lysergic acid (LSD) at a dose of 186 (nmol/kg)1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes.
AID178003Effective dose at which 50% of the rats tested selected the LSD-appropriate lever was reported; 0.029-0.0721985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives.
AID191405Compound was tested for hallucinogenic activity in rats at the dose of 0.04(mg/kg); Number of rats selecting the LSDlever/ number of rats responding (6/8)1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
AID170042Number of rats scored LSD correct/number tested was reported at a dose of 46.5 nM/Kg using 2-lever drug discrimination assay; 4/81985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives.
AID192223Percentage of animals emitting >80% of lever presses in rats at 0.01 mg/kg dose1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
AID175379Percentage of animals failing to emit 50 presses on either lever within the 15-min test period in rat at 0.01 mg/kg (0.023 uM/kg)1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
AID4761Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity.
AID3826Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID192205Percentage of animals emitting 50 presses on the LSD appropriate lever during the test period in rat at 0.02 mg/kg(0.046 uM/kg)1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
AID174862Hallucinogenic property was determined in groups of LSD trained rats and percentage of animals disrupted was reported at a dose 0.012 (umol/kg),(number of animals = 8)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID178195Effective dose in Drug Discrimination studies in LSD(d-lysergic acid N,N-diethylamide) trained rats. No. of animals tested 151996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups.
AID87691Binding affinity towards Histamine H1 receptor2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID192226Percentage of animals emitting >80% of lever presses in rats at 0.08 mg/kg dose1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
AID408465Displacement of [3H]INBMeO from human 5HT2A receptor expressed in human A549 cells2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.
AID189880Percentage of rats selecting the drug lever (% SDL) for dose 0.186 (umol/kg)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines.
AID178697Subcutaneous dose giving half-maximal decrease of 5-HTP formation in the rat brain hemispheres (cortex)1984Journal of medicinal chemistry, Jan, Volume: 27, Issue:1
8-Hydroxy-2-(alkylamino)tetralins and related compounds as central 5-hydroxytryptamine receptor agonists.
AID1865348Agonist activity at human 5HT2A S159A mutant transfected in HEK293T cells assessed as beta arrestin-2 recruitment measured for 2 hrs by luminescent assay2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT
AID224952Percentage of rats disrupted after 0.02 mg/kg, 0.046 uM/kg dose2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID178361Compound was tested for hallucinogenic activity in rats at the dose of 0.02(mg/kg)1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
AID4916Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID178581Effective dose to cause hallucinogenic activity in rats using drug discrimination assay by intraperitoneal administration1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and evaluation of substituted 2-phenylcyclobutylamines as analogues of hallucinogenic phenethylamines: lack of LSD-like biological activity.
AID6672Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Characterization of the 5-HT(7) receptor. Determination of the pharmacophore for 5-HT(7) receptor agonism and CoMFA-based modeling of the agonist binding site.
AID190085Tested for stimulus generation in rats trained to discriminate LSD from saline at a dose 0.023 (umol/kg) (number of animals = 8)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID191403Compound was tested for hallucinogenic activity in rats at the dose of 0.005(mg/kg); Number of rats selecting the LSDlever/ number of rats responding (4/8)1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
AID178197Effective dose in blocking conditioned avoidance responding (CAR) in the rat when administered intraperitoneally1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
AID4387Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.
AID3994Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups.
AID224957Percentage of rats disrupted after 0.04 mg/kg, 0.093 uM/kg dose2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID3192Efficacy against 5-hydroxytryptamine 2A receptor1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
AID190088Tested for stimulus generation in rats trained to discriminate LSD from saline at a dose 0.186 (umol/kg),(number of animals = 8)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID6574Binding affinities towards 5-hydroxytryptamine 6 receptor2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID6648Binding affinity towards rat 5-hydroxytryptamine 7 receptor2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
AID175380Percentage of animals failing to emit 50 presses on either lever within the 15-min test period in rat at 0.02 mg/kg(0.046 uM/kg)1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
AID5546Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes.
AID169910Number of rats scored LSD correct/number tested was reported at a dose of 185.5 nM/Kg using 2-lever drug discrimination assay; 8/81985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives.
AID189897Percentage of rats selecting the drug liver at dose of 0.08 mg/kg1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain.
AID192082Percentage of animals emitting 50 presses on the LSD appropriate lever during the test period i8n at 0.04 mg/kg (0.093 uM/kg)1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
AID178693Subcutaneous dose giving half-maximal decrease of 5-HTP formation in the rat brain (limbic)1984Journal of medicinal chemistry, Jan, Volume: 27, Issue:1
8-Hydroxy-2-(alkylamino)tetralins and related compounds as central 5-hydroxytryptamine receptor agonists.
AID176659Substitution tests were carried out for the compound in LSD- trained rats dosed with 0.046 uM/kg drug and the binding data was reported1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain.
AID178743Effective dose was evaluated for drug discrimination in I-trained rats1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA).
AID175224Percentage of animals failing to emit 50 lever presses within 15 min in at 0.01 mg/kg dose1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
AID174864Hallucinogenic property was determined in groups of LSD trained rats and percentage of animals disrupted was reported at a dose 0.093(umol/kg) (number of animals = 8)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID175381Percentage of animals failing to emit 50 presses on either lever within the 15-min test period in rat at 0.04 mg/kg (0.093 uM/kg)1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
AID175225Percentage of animals failing to emit 50 lever presses within 15 min in rats at 0.02 mg/kg dose1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
AID189876Percentage of rats selecting the drug lever (% SDL) for dose 0.012 (umol/kg)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines.
AID191407Compound was tested for hallucinogenic activity in rats at the dose of 0.01(mg/kg); Number of rats selecting the LSDlever/ number of rats responding (4/8)1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
AID5590Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-632002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID40552Binding affinity towards Beta-1 adrenergic receptor2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID176460Potency of compound in 1-trained rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane.
AID176237Inhibitory activity was determined LSD trained rats1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID189892Percentage of rats selecting the drug liver at dose of 0.01 mg/kg1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain.
AID4044Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes.
AID192083Percentage of animals emitting 50 presses on the LSD appropriate lever during the test period in at 0.08 mg/kg (0.186 uM/kg)1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
AID189877Percentage of rats selecting the drug lever (% SDL) for dose 0.024(umol/kg)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines.
AID6666Binding affinity at rat 5-hydroxytryptamine 7 receptor.2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Characterization of the 5-HT(7) receptor. Determination of the pharmacophore for 5-HT(7) receptor agonism and CoMFA-based modeling of the agonist binding site.
AID175382Percentage of animals failing to emit 50 presses on either lever within the 15-min test period in rat at 0.08 mg/kg (0.186 uM/kg)1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
AID1865345Agonist activity at human 5HT2A receptor transfected in HEK293T cells assessed as beta arrestin-2 recruitment measured for 2 hrs by luminescent assay relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT
AID225144Effective dose in rats after 0.04 mg/kg, 0.093 uM/kg dose (95%CI)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID1865344Agonist activity at human 5HT2A receptor transfected in HEK293T cells assessed as beta arrestin-2 recruitment measured for 2 hrs by luminescent assay2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT
AID5738In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
AID5001Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity.
AID192085Percentage of animals emitting 50 presses on the LSD appropriate lever during the test period in rat at 0.01 mg/kg (0.023 uM/kg)1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
AID64142Binding affinity towards Dopamine receptor D22002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID6689Binding affinities towards 5-hydroxytryptamine 7 receptor2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID190086Tested for stimulus generation in rats trained to discriminate LSD from saline at a dose 0.046(umol/kg) (number of animals = 9)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID6611Binding affinity against 5-hydroxytryptamine 7 human receptors2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
A novel ergot alkaloid as a 5-HT(1A) inhibitor produced by Dicyma sp.
AID5726Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID174857Hallucinogenic property was determined in groups of LSD trained rats and percentage of animals disrupted was reported at 0.023 (umol/kg) (number of animals = 8)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID192250Percentage of animals selecting drug lever at a dose 93 nmol/kg1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane.
AID190084Tested for stimulus generation in rats trained to discriminate LSD from saline at a dose 0.012 (umol/kg),(number of animals = 8)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID189895Percentage of rats selecting the drug liver at dose of 0.04 mg/kg1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain.
AID174715Compound was tested for its effect on animals. Value reported as number of rats disrupted in trained rats at a dose of 186 (nmol/kg)1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes.
AID192248Percentage of animals selecting drug lever at a dose 47nmol/kg1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane.
AID6502Binding affinities towards 5-hydroxytryptamine 5A receptor2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID5224Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines.
AID3854Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
AID3925Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
A novel ergot alkaloid as a 5-HT(1A) inhibitor produced by Dicyma sp.
AID175226Percentage of animals failing to emit 50 lever presses within 15 min in rats at 0.04 mg/kg dose1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
AID267699Displacement of [125I]DOI from rat 5HT2C receptor2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor.
AID101152Evaluated in the two-lever drug discrimination assay in LSD trained rats to assess hallucinogenic-like activity (95% confidence intervals)2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.
AID224832Percentage of rats disrupted after 0.08 mg/kg, 0.186 uM/kg dose (95%CI)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID63247Binding affinity against human Dopamine receptor D2 in CHO cells using [125I]iodosulpiride2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
A novel ergot alkaloid as a 5-HT(1A) inhibitor produced by Dicyma sp.
AID191404Compound was tested for hallucinogenic activity in rats at the dose of 0.02(mg/kg); Number of rats selecting the LSDlever/ number of rats responding (5/8)1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
AID441162Dissociation constant, pKa at pH 7.42009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.
AID192224Percentage of animals emitting >80% of lever presses in rats at 0.02 mg/kg dose1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
AID5829Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID176459Potency against LSD trained rat, activity is expressed as ED501995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines.
AID337898Displacement of [3H]ketanserin from 5HT2 receptor1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID4971Binding affinity towards 5-hydroxytryptamine 1E receptor2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID65784Binding affinity towards Dopamine receptor D32002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID408464Displacement of [3H]ketanserin from human 5HT2A receptor expressed in human A549 cells2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.
AID191402Compound was tested for hallucinogenic activity in rats at the dose of 0.0025 (mg/kg); Number of rats selecting the LSDlever/ number of rats responding (0/8)1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
AID178695Subcutaneous dose giving half-maximal decrease of 5-HTP formation in the rat brain (striatum)1984Journal of medicinal chemistry, Jan, Volume: 27, Issue:1
8-Hydroxy-2-(alkylamino)tetralins and related compounds as central 5-hydroxytryptamine receptor agonists.
AID4261Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
A novel ergot alkaloid as a 5-HT(1A) inhibitor produced by Dicyma sp.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID1865350Agonist activity at human 5HT2A S159A mutant transfected in HEK293T cells assessed as mini Galphaq recruitment measured for 2 hrs by luminescent assay2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT
AID189878Percentage of rats selecting the drug lever (% SDL) for dose 0.047(umol/kg)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines.
AID226641Hill coefficient of the compound1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines.
AID192249Percentage of animals selecting drug lever at a dose 6 nmol/kg1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane.
AID225141Effective dose in rats as nmol/kg after 0.04 mg/kg, 0.093 uM/kg dose (95%CI)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID178199Effective dose in trained rats was determined at a dose of 186 (nmol/kg)1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes.
AID337897Displacement of [3H]5HT from 5HT1 receptor1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID4211Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane.
AID174865Hallucinogenic property was determined in groups of LSD trained rats and percentage of animals disrupted was reported at a dose 0.186 (umol/kg),(number of animals = 8)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
AID267700Activity at rat 5HT2A receptor assessed as 5-HT-stimulated IP3 accumulation2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor.
AID178699Compound was tested for subcutaneous dose giving half-maximal decrease of Dopa formation in the rat brain (limbic)1984Journal of medicinal chemistry, Jan, Volume: 27, Issue:1
8-Hydroxy-2-(alkylamino)tetralins and related compounds as central 5-hydroxytryptamine receptor agonists.
AID267698Displacement of [125I]DOI from rat 5HT2A receptor2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor.
AID226143Percentage of rats selecting drug lever (SDL) after 0.08 mg/kg, 0.186 uM/kg dose2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID188175Potency ratio was obtained using a 3 point x 3 point parallel-line bioassay for quantal data and reflects the potency relative to LSD1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives.
AID177093Drug discrimination studies in rats(22) expressed as ED50 values1998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor.
AID226148Percentage of rats selecting the drug lever (SDL) after 0.02 mg/kg, 0.046 uM/kg dose2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID267701Hallucinogenic activity in rat2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID5463Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID192242Percentage of animals selecting drug lever at a dose 23 nmol/kg1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane.
AID185557Maximum 5-HT stimulation was determined in cloned rats2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
AID224835Percentage of rats disrupted after 0.01 mg/kg, 0.023 uM/kg dose2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID189879Percentage of rats selecting the drug lever (% SDL) for dose 0.093(umol/kg)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines.
AID170035Number of rats scored LSD correct/number tested was reported at a dose of 23 nM/Kg using 2-lever drug discrimination assay; 2/81985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives.
AID189547Potency of compound in 1-trained rats measured as ED50 relative to LSD1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane.
AID1865347Agonist activity at human 5HT2A receptor transfected in HEK293T cells assessed as mini Galphaq recruitment measured for 2 hrs by luminescent assay relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT
AID5523Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups.
AID191406Compound was tested for hallucinogenic activity in rats at the dose of 0.08(mg/kg); Number of rats selecting the LSDlever/ number of rats responding (8/8)1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
AID178701Compound was tested for subcutaneous dose giving half-maximal decrease of Dopa formation in the rat brain (striatum)1984Journal of medicinal chemistry, Jan, Volume: 27, Issue:1
8-Hydroxy-2-(alkylamino)tetralins and related compounds as central 5-hydroxytryptamine receptor agonists.
AID197406Effective dose for drug discrimination assay in rats using LSD as training drug1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA).
AID408466Displacement of [3H]ketanserin from human 5HT2A receptor expressed in human HEK293 cells2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.
AID5537Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID5650Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
A novel ergot alkaloid as a 5-HT(1A) inhibitor produced by Dicyma sp.
AID192259Percentage of animals selecting drug lever in trained rats at a dose 186 (nmol/kg)1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes.
AID185149Compound was evaluated for the drug discrimination assay and the highest percent of LSD correct responses were determined in rats1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Substituent branching in phenethylamine-type hallucinogens: a comparison of 1-[2,5-dimethoxy-4-(2-butyl)phenyl]-2-aminopropane and 1-[2,5-dimethoxy-4-(2-methylpropyl)phenyl]-2-aminopropane.
AID61837Binding affinities towards Dopamine receptor D12002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID29136Acid dissociation constant was determined1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Synthesis and serotonin-like activity of 2-amino-5,8-dimethoxy-6-methyl-1,2-dihydronaphthalene.
AID1865349Agonist activity at human 5HT2A S159A mutant transfected in HEK293T cells assessed as beta arrestin-2 recruitment measured for 2 hrs by luminescent assay relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID624240Agonists at Rat 5-Hydroxytryptamine receptor 5-HT2B2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID624210Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID624216Agonists at Human 5-Hydroxytryptamine receptor 5-HT2C2000Synapse (New York, N.Y.), Feb, Volume: 35, Issue:2
Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)2000Synapse (New York, N.Y.), Feb, Volume: 35, Issue:2
Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.
AID1345154Rat 5-HT6 receptor (5-Hydroxytryptamine receptors)
AID1346903Rat 5-HT2B receptor (5-Hydroxytryptamine receptors)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID1345170Human 5-HT6 receptor (5-Hydroxytryptamine receptors)1998Molecular pharmacology, Sep, Volume: 54, Issue:3
The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum.
AID624234Agonists at Rat 5-Hydroxytryptamine receptor 5-HT2A2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
AID624235Agonists at Human 5-Hydroxytryptamine receptor 5-HT2A1996The Journal of biological chemistry, Jun-21, Volume: 271, Issue:25
Mapping the binding site pocket of the serotonin 5-Hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)2013Science (New York, N.Y.), May-03, Volume: 340, Issue:6132
Structural features for functional selectivity at serotonin receptors.
AID1345154Rat 5-HT6 receptor (5-Hydroxytryptamine receptors)1998Molecular pharmacology, Sep, Volume: 54, Issue:3
The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum.
AID1259419Human 5-HT2A receptor (5-Hydroxytryptamine receptors)1996The Journal of biological chemistry, Jun-21, Volume: 271, Issue:25
Mapping the binding site pocket of the serotonin 5-Hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin.
AID1346919Rat 5-HT2A receptor (5-Hydroxytryptamine receptors)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,764)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903776 (79.26)18.7374
1990's301 (6.32)18.2507
2000's216 (4.53)29.6817
2010's226 (4.74)24.3611
2020's245 (5.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 112.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index112.41 (24.57)
Research Supply Index8.58 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index212.77 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (112.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials161 (3.13%)5.53%
Reviews395 (7.68%)6.00%
Case Studies157 (3.05%)4.05%
Observational4 (0.08%)0.25%
Other4,429 (86.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (21)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Mood Effects of Serotonin Agonists [NCT03790358]Phase 140 participants (Anticipated)Interventional2018-05-01Recruiting
Efficacy and Safety of Minidosing Lysergic Acid Diethylamide (LSD) for Chronic Cluster Headache: a Randomized Placebo-controlled Study [NCT05477459]Phase 265 participants (Anticipated)Interventional2024-01-31Not yet recruiting
LSD-assisted Psychotherapy in Persons Suffering From Anxiety Associated With Advanced-stage Life Threatening Diseases. A Phase-II, Double-blind, Placebo-controlled Dose-response Pilot Study [NCT00920387]Phase 212 participants (Actual)Interventional2008-02-29Completed
Effect of Ketanserin After LSD Administration on the Acute Response to LSD in Healthy Subjects [NCT04558294]Phase 124 participants (Actual)Interventional2020-10-16Completed
The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality [NCT05670184]Phase 1/Phase 260 participants (Anticipated)Interventional2023-01-01Recruiting
Effects of Lysergic Acid Diethylamide (LSD) on Neuroplasticity in Healthy Human Subjects [NCT05177419]Phase 140 participants (Anticipated)Interventional2022-05-02Recruiting
LSD Therapy for Persons Suffering From Major Depression: A Randomised, Double-blind, Active-placebo Controlled Phase II Study [NCT03866252]Phase 260 participants (Actual)Interventional2019-11-01Completed
Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study) [NCT03321136]Early Phase 116 participants (Actual)Interventional2017-11-28Completed
Safety and Efficacy of Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache: a Randomized, Double-blind, Placebo-controlled Phase II Study [NCT03781128]Phase 230 participants (Anticipated)Interventional2019-01-02Recruiting
Effects of LSD on Perceptual Decision-making in Healthy Subjects [NCT05976698]30 participants (Anticipated)Interventional2023-09-30Not yet recruiting
Lysergic Acid Diethylamide Occupancy of the Serotonin 2A Receptor in the Human Brain [NCT05953038]Early Phase 140 participants (Anticipated)Interventional2023-11-08Recruiting
Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study [NCT01878942]Early Phase 116 participants (Actual)Interventional2013-06-30Completed
A Phase 1, Single-centre, Dose-escalation Study Utilising Both Open-label and Double-blind Placebo-controlled Crossover Design Studies to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Low Doses of Lysergic Acid Diethylamide [NCT05674669]Phase 132 participants (Actual)Interventional2015-10-20Completed
Effects of Serotonin Transporter Inhibition on the Subjective Response to LSD in Healthy Subjects [NCT05175430]Phase 124 participants (Anticipated)Interventional2022-10-24Active, not recruiting
Neuronal Correlates of Altered States of Consciousness [NCT02308969]Early Phase 124 participants (Actual)Interventional2014-12-31Completed
Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study) [NCT05883540]Phase 260 participants (Anticipated)Interventional2023-09-30Recruiting
Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing [NCT03019822]Early Phase 128 participants (Actual)Interventional2017-02-01Completed
LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects [NCT04865653]Phase 120 participants (Anticipated)Interventional2022-03-17Recruiting
Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects [NCT04516902]Phase 124 participants (Actual)Interventional2021-01-01Completed
The Role of 5-HT2A Receptor on Perception of the Self and Perception of Meaning in Healthy Volunteers [NCT02451072]25 participants (Actual)Interventional2015-03-31Completed
A Phase 1,Single-centre, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Very Low Dose LSD (5 µg, 10 µg, 20 µg) in Healthy Volunteers Aged 55-75 Years [NCT04421105]Phase 148 participants (Actual)Interventional2015-06-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00920387 (2) [back to overview]Baseline State-Trait Anxiety Inventory (STAI)
NCT00920387 (2) [back to overview]Primary Endpoint State-Trait Anxiety Inventory (STAI)

Baseline State-Trait Anxiety Inventory (STAI)

"The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The STAI-state subscale is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Participants respond to each item by selecting a response from a 4-point Likert scale ranging from 4 (Not at all) to 1 (Very much so). STAI-state scores are summed for a total score that range from 20 to 80, with higher scores indicating greater state anxiety. The STAI-trait subscale also consists of 20-items and is scored the same way, with total scores ranging from 20 to 80, with higher scores indicating greater trait anxiety." (NCT00920387)
Timeframe: Baseline (Visit 4)

,
Interventionscore on a scale (Mean)
STAI-stateSTAI-trait
Active Placebo LSD (20 mcg)47.743.3
Full Dose LSD (200 mcg)53.153.2

[back to top]

Primary Endpoint State-Trait Anxiety Inventory (STAI)

"The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The STAI-state subscale is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Participants respond to each item by selecting a response from a 4-point Likert scale ranging from 4 (Not at all) to 1 (Very much so). STAI-state scores are summed for a total score that range from 20 to 80, with higher scores indicating greater state anxiety. The STAI-trait subscale also consists of 20-items and is scored the same way, with total scores ranging from 20 to 80, with higher scores indicating greater trait anxiety." (NCT00920387)
Timeframe: 2 months after second experimental session

,
Interventionscore on a scale (Mean)
STAI-stateSTAI-trait
Active Placebo LSD (20 mcg)51.749.0
Full Dose LSD (200 mcg)41.545.2

[back to top]